Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

Clinical trial NCT02286687 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT02286687
Sponsor: M.D. Anderson Cancer Center
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Advanced Malignant Neoplasm ATM Gene Mutation BRCA1 Gene Mutation BRCA2 Gene Mutation Metastatic Malignant Neoplasm PALB2 Gene Mutation Recurrent Malignant Neoplasm Refractory Malignant Neoplasm

Start date: 2014-12-22
Primary completion: 2026-12-31
Enrollment: 150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.